Integrated In Vitro/Ex Vivo Assessment of Efficacy and Respiratory Toxicity for Accelerated Respiratory Drug Development
K Schwarz, F Dahlmann, D Winterberg… - B67. VIRAL …, 2024 - atsjournals.org
Rationale: To support preclinical development of drugs, predictive models for early PoC
represent an important contribution. We have developed an integrative approach for early …
represent an important contribution. We have developed an integrative approach for early …
[HTML][HTML] Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
AJ McAuley, P Jansen van Vuren, MUR Mohammed… - Viruses, 2022 - mdpi.com
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways
to develop new and alternative therapeutic options to manage the ongoing pandemic. Given …
to develop new and alternative therapeutic options to manage the ongoing pandemic. Given …
Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
S Murugesan - 2022 - dspace.bits-pilani.ac.in
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways
to develop new and alternative therapeutic options to manage the ongoing pandemic. Given …
to develop new and alternative therapeutic options to manage the ongoing pandemic. Given …
[HTML][HTML] Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches
C Davis, RD Mann, AJ Hickey, H Olafsson, BA Fowler… - everand.com
Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy
and safety of these medicines can be influenced by the deposited fraction, the regional …
and safety of these medicines can be influenced by the deposited fraction, the regional …
Ex Vivo Models for Predictive Testing of Inhalable Anti-infectives in Early Pre-clinical Development
K Schwarz - A62. BACTERIA, FIND OUT WHAT IT MEANS TO ME, 2023 - atsjournals.org
Inhalation administration of anti-infective drugs into the lung to directly address the site of
infection is an attractive option for treatment of respiratory diseases. For a faster and cost …
infection is an attractive option for treatment of respiratory diseases. For a faster and cost …
A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds …
L Lopez Quezada, F Mba Medie, EP Gabriel, RJ Luu… - bioRxiv, 2023 - biorxiv.org
The COVID-19 pandemic necessitated a rapid mobilization of resources toward the
development of safe and efficacious vaccines and therapeutics. Finding effective treatments …
development of safe and efficacious vaccines and therapeutics. Finding effective treatments …
Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform
CR Fisher, FM Medie, RJ Luu, LL Quezada, RB Gaibler… - bioRxiv, 2022 - biorxiv.org
Despite the relatively common observation of therapeutic efficacy in discovery screens with
immortalized cell lines, the vast majority of drug candidates do not reach clinical …
immortalized cell lines, the vast majority of drug candidates do not reach clinical …
[图书][B] Inhaled Medicines: Optimizing Development Through Integration of in Silico, in Vitro and in Vivo Approaches
Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy
and safety of these medicines can be influenced by the deposited fraction, the regional …
and safety of these medicines can be influenced by the deposited fraction, the regional …
[PDF][PDF] In-silico lung modeling platform for inhaled drug delivery
The inability to measure local lung concentrations responsible for lung efficacy is the main
challenge common to any inhalation drug delivery program targeting the lungs. The model …
challenge common to any inhalation drug delivery program targeting the lungs. The model …
[引用][C] Use of Human Lung Tissue Models for Screening of Drugs Against SARS-CoV-2 Infection (preprint)
AJ McAuley, PJ van Vuren, F Faheem, S Goldie… - 2022